PeptiDream (4587) 주식 개요
바이오 제약 회사인 펩티드림은 제약 펩타이드, 저분자 및 펩타이드-약물 접합 치료제를 발견하고 개발하는 회사입니다. 자세히 보기
4587 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
PeptiDream Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | JP¥1,215.50 |
| 52주 최고가 | JP¥1,818.50 |
| 52주 최저가 | JP¥1,058.50 |
| 베타 | 0.17 |
| 1개월 변동 | 6.53% |
| 3개월 변동 | -10.53% |
| 1년 변동 | -27.37% |
| 3년 변동 | -36.09% |
| 5년 변동 | -76.12% |
| IPO 이후 변동 | 69.11% |
최근 뉴스 및 업데이트
내러티브 업데이트 • May 08
4587: Out Licensing Progress And Autoimmune Pipeline Will Support Future Upside
Analysts have trimmed their price target on PeptiDream to ¥1,600 from ¥2,600, citing slower than expected progress in product out licensing and adjustments to fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Analyst Commentary Bearish analysts are flagging that the lower ¥1,600 price target reflects reduced confidence in how quickly PeptiDream can execute on its product out licensing plans and convert its pipeline into revenue.
내러티브 업데이트 • Apr 23
4587: Out Licensing Milestones Will Eventually Support Stronger Long Term Earnings Visibility
Analysts have reduced their price target on PeptiDream to ¥1,600 from ¥2,700, citing slower than expected progress in product out-licensing as the main reason for the adjustment. Analyst Commentary Bullish Takeaways Bullish analysts still see value at the revised price target of ¥1,600, arguing that expectations now better reflect the current pace of out-licensing activity.내러티브 업데이트 • Apr 08
4587: Out Licensing Progress Will Support Stronger Long Term Earnings Visibility
Analysts have lowered their price target on PeptiDream to ¥2,825 from ¥3,008, citing slightly reduced fair value assumptions following slower than expected product out licensing, as reflected in updated discount rate, revenue growth, profit margin, and future P/E inputs. Analyst Commentary Recent research points to a more cautious stance on PeptiDream, with rating and target price adjustments linked mainly to timing risks around product out licensing.
내러티브 업데이트 • Mar 25
4587: Out Licensing Progress And 2026 Earnings Targets Will Drive Future Upside
Analysts have modestly raised their fair value estimate for PeptiDream to ¥4,400 from ¥4,255, citing updated assumptions around discount rate, revenue growth, profit margin, and forward P/E, even as some have turned more cautious with a lower Street price target of ¥1,600 reflecting slower than expected product out licensing. Analyst Commentary Recent Street commentary highlights a mix of caution on timing of product out licensing and incremental confidence in PeptiDream's long term potential, reflected in the modest lift in fair value estimates despite a lower Street price target concentrated around ¥1,600.Recent updates
내러티브 업데이트 • May 08
4587: Out Licensing Progress And Autoimmune Pipeline Will Support Future Upside
Analysts have trimmed their price target on PeptiDream to ¥1,600 from ¥2,600, citing slower than expected progress in product out licensing and adjustments to fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Analyst Commentary Bearish analysts are flagging that the lower ¥1,600 price target reflects reduced confidence in how quickly PeptiDream can execute on its product out licensing plans and convert its pipeline into revenue.내러티브 업데이트 • Apr 23
4587: Out Licensing Milestones Will Eventually Support Stronger Long Term Earnings Visibility
Analysts have reduced their price target on PeptiDream to ¥1,600 from ¥2,700, citing slower than expected progress in product out-licensing as the main reason for the adjustment. Analyst Commentary Bullish Takeaways Bullish analysts still see value at the revised price target of ¥1,600, arguing that expectations now better reflect the current pace of out-licensing activity.내러티브 업데이트 • Apr 08
4587: Out Licensing Progress Will Support Stronger Long Term Earnings Visibility
Analysts have lowered their price target on PeptiDream to ¥2,825 from ¥3,008, citing slightly reduced fair value assumptions following slower than expected product out licensing, as reflected in updated discount rate, revenue growth, profit margin, and future P/E inputs. Analyst Commentary Recent research points to a more cautious stance on PeptiDream, with rating and target price adjustments linked mainly to timing risks around product out licensing.내러티브 업데이트 • Mar 25
4587: Out Licensing Progress And 2026 Earnings Targets Will Drive Future Upside
Analysts have modestly raised their fair value estimate for PeptiDream to ¥4,400 from ¥4,255, citing updated assumptions around discount rate, revenue growth, profit margin, and forward P/E, even as some have turned more cautious with a lower Street price target of ¥1,600 reflecting slower than expected product out licensing. Analyst Commentary Recent Street commentary highlights a mix of caution on timing of product out licensing and incremental confidence in PeptiDream's long term potential, reflected in the modest lift in fair value estimates despite a lower Street price target concentrated around ¥1,600.내러티브 업데이트 • Mar 10
4587: Oral Autoimmune Pipeline And siRNA Milestones Will Support Stronger Long Term Outlook
Analysts now set their PeptiDream price target at ¥3,008, down slightly from ¥3,033, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E. What's in the News PeptiDream issued consolidated earnings guidance for the fiscal year ending December 31, 2026, with expected revenue of ¥32,000 million, core operating profit and operating profit of ¥4,600 million, and profit attributable to owners of parent of ¥3,000 million (Corporate guidance).내러티브 업데이트 • Feb 24
4587: Expanded Oral Pipeline And 2026 Milestones Will Drive Future Upside Potential
Analysts have slightly adjusted their price target on PeptiDream to ¥4,255 from ¥4,281 to reflect updated views on fair value, alongside refreshed assumptions for revenue growth, profit margin, discount rate and future P/E. What's in the News PeptiDream issued consolidated earnings guidance for the fiscal year ending December 31, 2026, expecting revenue of ¥32,000 million, core operating profit and operating profit of ¥4,600 million, and profit attributable to owners of parent of ¥3,000 million.분석 기사 • Feb 18
Analysts Have Lowered Expectations For PeptiDream Inc. (TSE:4587) After Its Latest Results
There's been a notable change in appetite for PeptiDream Inc. ( TSE:4587 ) shares in the week since its yearly report...내러티브 업데이트 • Feb 09
4587: Oral Autoimmune Pipeline Progress Will Drive Stronger Long Term Outlook
Analysts have trimmed their price target on PeptiDream to reflect a fair value of ¥3,033, down from ¥3,271, as they factor in slightly softer revenue growth and profit margin assumptions, along with a modestly higher discount rate and P/E multiple outlook. What's in the News PeptiDream reported a revision to its fiscal year 2025 guidance, now expecting revenue of ¥18,000 million instead of ¥49,000 million, with an operating loss of ¥5,400 million and a loss attributable to owners of parent of ¥4,000 million, citing delays in anticipated milestones and partnering deals including its oral myostatin program.내러티브 업데이트 • Jan 26
4587: Milestone Progress In RNAi Delivery Platform Will Support Future Upside
Analysts now mark their fair value estimate for PeptiDream at ¥2,600, up from ¥2,500, reflecting adjustments to discount rates, revenue growth assumptions, profit margins, and a higher future P/E multiple. What's in the News PeptiDream reported a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals, supporting a modular platform for precision siRNA delivery using macrocyclic peptides to target organs beyond the liver, with associated milestone payments and potential future royalties from Alnylam products (Key Developments).내러티브 업데이트 • Jan 12
4587: Expanded Pipeline Milestones Will Drive Future Upside Potential
Analysts have reduced their price expectations for PeptiDream, reflecting updated assumptions for slightly lower revenue growth and profit margins, along with a higher future P/E multiple. Together, these changes reduce the implied upside from prior targets on a discounted cash flow basis.내러티브 업데이트 • Dec 17
4587: Rebound In Partnering Revenues Will Drive Strong Upside Potential
Analysts have trimmed their price target on PeptiDream from ¥4,830 to ¥4,281, reflecting a slightly higher discount rate, even as they modestly raise long term revenue growth and profit margin assumptions and apply a lower future P E multiple. What's in the News PeptiDream sharply cut its FY25 revenue guidance to JPY 18 billion from JPY 49 billion, and now expects an operating loss of JPY 5.4 billion instead of a JPY 21.6 billion profit, as milestone and partnering revenues shift into FY26 (company guidance).분석 기사 • Dec 04
This Just In: Analysts Are Boosting Their PeptiDream Inc. (TSE:4587) Outlook for Next Year
Shareholders in PeptiDream Inc. ( TSE:4587 ) may be thrilled to learn that the analysts have just delivered a major...내러티브 업데이트 • Dec 03
4587: Radiopharmaceutical Pipeline Progress Will Drive Stronger Long Term Outlook
Analysts have modestly reduced their price target on PeptiDream from ¥3,414 to ¥3,271 as they incorporate a slightly higher discount rate, even as they update their assumptions to reflect stronger revenue growth, improved profitability, and a lower future P/E multiple. What's in the News PeptiDream, PDRadiopharma, and Curium have initiated a registrational Phase 2 clinical trial in Japan for 64Cu-PSMA-I&T, a PET radiopharmaceutical targeting PSMA expressed on prostate cancer cells (Key Developments).분석 기사 • Oct 05
Is PeptiDream (TSE:4587) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...내러티브 업데이트 • Sep 05
AI Discovery And Peptide Pipeline Will Expand Horizons
With both the discount rate and future P/E multiple showing only negligible movement, there has been no material change to PeptiDream's consensus analyst fair value, which remains steady at ¥3414. Valuation Changes Summary of Valuation Changes for PeptiDream The Consensus Analyst Price Target remained effectively unchanged, at ¥3414.분석 기사 • Jun 23
PeptiDream (TSE:4587) Seems To Use Debt Rather Sparingly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Apr 17
Here's Why We Think PeptiDream (TSE:4587) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
새로운 내러티브 • Mar 10
Advancements In Radiopharmaceutical Pipeline And Novartis Deal Will Drive Future Success
Expansion of deals and strategic partnerships positions PeptiDream for substantial future revenue growth from clinical advancements and imaging collaborations.분석 기사 • Mar 08
PeptiDream (TSE:4587) Has A Rock Solid Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Feb 19
Bullish: Analysts Just Made A Decent Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts
Shareholders in PeptiDream Inc. ( TSE:4587 ) may be thrilled to learn that the analysts have just delivered a major...분석 기사 • Feb 17
Earnings Miss: PeptiDream Inc. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts
It's been a pretty great week for PeptiDream Inc. ( TSE:4587 ) shareholders, with its shares surging 18% to JP¥2,328 in...분석 기사 • Feb 14
PeptiDream Inc.'s (TSE:4587) Price Is Out Of Tune With Earnings
When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 13x, you may consider...분석 기사 • Dec 22
Are Investors Undervaluing PeptiDream Inc. (TSE:4587) By 39%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, PeptiDream fair value estimate is JP¥4,230 PeptiDream is...분석 기사 • Nov 21
PeptiDream's (TSE:4587) Performance Is Even Better Than Its Earnings Suggest
Even though PeptiDream Inc.'s ( TSE:4587 ) recent earnings release was robust, the market didn't seem to notice...분석 기사 • Nov 18
PeptiDream Inc. Just Missed Earnings; Here's What Analysts Are Forecasting Now
It's been a good week for PeptiDream Inc. ( TSE:4587 ) shareholders, because the company has just released its latest...분석 기사 • Nov 15
Is PeptiDream (TSE:4587) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Oct 31
PeptiDream Inc.'s (TSE:4587) Price Is Out Of Tune With Earnings
When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 13x, you may consider...분석 기사 • Oct 15
Do PeptiDream's (TSE:4587) Earnings Warrant Your Attention?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...분석 기사 • Aug 29
PeptiDream Inc. (TSE:4587) Shares Could Be 37% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, PeptiDream fair value estimate is JP¥4,180 Current share price...분석 기사 • Aug 12
PeptiDream Inc. Just Beat Revenue Estimates By 13%
Shareholders of PeptiDream Inc. ( TSE:4587 ) will be pleased this week, given that the stock price is up 11% to...분석 기사 • Jun 30
PeptiDream Inc. (TSE:4587) Surges 27% Yet Its Low P/S Is No Reason For Excitement
PeptiDream Inc. ( TSE:4587 ) shares have continued their recent momentum with a 27% gain in the last month alone...분석 기사 • Jun 02
News Flash: Analysts Just Made A Meaningful Upgrade To Their PeptiDream Inc. (TSE:4587) Forecasts
Celebrations may be in order for PeptiDream Inc. ( TSE:4587 ) shareholders, with the analysts delivering a significant...분석 기사 • Apr 30
PeptiDream Inc.'s (TSE:4587) 42% Price Boost Is Out Of Tune With Revenues
PeptiDream Inc. ( TSE:4587 ) shares have continued their recent momentum with a 42% gain in the last month alone...분석 기사 • Apr 29
Is PeptiDream Inc. (TSE:4587) Trading At A 46% Discount?
Key Insights PeptiDream's estimated fair value is JP¥3,010 based on 2 Stage Free Cash Flow to Equity Current share...분석 기사 • Mar 03
PeptiDream Inc.'s (TSE:4587) 25% Jump Shows Its Popularity With Investors
PeptiDream Inc. ( TSE:4587 ) shareholders would be excited to see that the share price has had a great month, posting a...주주 수익률
| 4587 | JP Biotechs | JP 시장 | |
|---|---|---|---|
| 7D | 7.9% | -3.0% | 1.2% |
| 1Y | -27.4% | -11.3% | 42.1% |
수익률 대 산업: 4587은 지난 1년 동안 -11.3%의 수익을 기록한 JP Biotechs 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: 4587은 지난 1년 동안 42.1%를 기록한 JP 시장보다 저조한 성과를 냈습니다.
주가 변동성
| 4587 volatility | |
|---|---|
| 4587 Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in JP Market | 9.6% |
| 10% least volatile stocks in JP Market | 2.5% |
안정적인 주가: 4587는 지난 3개월 동안 JP 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: 4587의 주간 변동성(7%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2006 | 645 | Patrick Crawford Reid | www.peptidream.com |
바이오 제약 회사인 펩티드림은 제약 펩타이드, 저분자 및 펩타이드-약물 접합 치료제의 발견과 개발에 종사하고 있습니다. 이 회사는 강력하고 선택적인 거대 고리형 펩타이드 후보를 식별하기 위해 비표준 펩타이드 라이브러리를 생산할 수 있는 약물 탐색 플랫폼인 펩타이드 디스커버리 플랫폼 시스템을 기반으로 제품을 개발하며, 이를 펩타이드 기반, 저분자 기반, 펩타이드-약물 접합체, 다기능 펩타이드 접합체 기반 치료제 및 진단으로 개발할 수 있습니다. 개발 파이프라인으로는 종양 치료제로서 현재 임상 1상 개발 단계에 있는 PD-L1, 종양 치료제로서 현재 임상 1상 개발 단계에 있는 PD-L1 BMS-986229, 다발성 골수종 치료제로서 현재 임상 1상 개발 단계에 있는 CD38 BHV-1100 + NK 세포, COVID-19 치료제로서 현재 임상 1상 개발 단계에 있는 S2-protein PA-001, 비대증/NET 치료제이며 현재 임상 1상 개발 단계인 GhR AZP-3813이 있습니다; 간암에 대한 적응증으로 현재 전임상 개발 단계에 있는 글리피칸-3, DMD/근육 질환에 대한 적응증으로 현재 전임상 개발 단계에 있는 미오스타틴, 신경근육 질환에 대한 적응증으로 현재 전임상 개발 단계에 있는 TfR, 알레르기 질환에 대한 적응증으로 현재 전임상 개발 단계에 있는 c-Kit, 현재 전임상 개발 단계에 있는 c-Met, 인플루엔자로 적응증에 있는 HA 단백질, 현재 전임상 개발 단계에 있는 단백질 등입니다.
PeptiDream Inc. 기초 지표 요약
| 4587 기초 통계 | |
|---|---|
| 시가총액 | JP¥157.06b |
| 순이익 (TTM) | -JP¥3.57b |
| 매출 (TTM) | JP¥19.05b |
8.2x
주가매출비율(P/S)-44.0x
주가수익비율(P/E)4587는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| 4587 손익계산서 (TTM) | |
|---|---|
| 매출 | JP¥19.05b |
| 매출원가 | JP¥10.97b |
| 총이익 | JP¥8.08b |
| 기타 비용 | JP¥11.65b |
| 순이익 | -JP¥3.57b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -27.63 |
| 총이익률 | 42.41% |
| 순이익률 | -18.74% |
| 부채/자본 비율 | 32.8% |
4587의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/22 12:58 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
PeptiDream Inc.는 14명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Shan He | Bernstein |
| Hidemaru Yamaguchi | Citigroup Inc |
| Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. |